Results 61 to 70 of about 610,146 (137)

Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases.

, 2010
The human pathogen Staphylococcus aureus produces several complement-evasion molecules that enable the bacterium to withstand the host immune response. The human-specific staphylococcal complement inhibitor (SCIN) blocks the central C3 convertase enzymes
Jongerius, I, Ruyken, M, van Strijp, JA, Rooijakkers, SH, Wu, J, Jongerius, Ilse, Puister, M   +6 more
core   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Complement C5 [PDF]

, 2012
Complement C5 is a 189 kDa protein synthesized in liver as a single-chain precursor molecule. The precursor molecule is then cleaved to a disulfide linked two-chain glycoprotein consisting of a 115 kDa (C5α) and a 75 kDa N-terminal (C5β) chain.
Dinasarapu, Ashok Reddy, Subramaniam, Shankar, Chandrasekhar, Anjana, Isenman, David E.   +3 more
core   +1 more source

C3 glomerulopathy — understanding a rare complement-driven renal disease

, 2019
\ua9 2019, Springer Nature Limited. The C3 glomerulopathies are a group of rare kidney diseases characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 ...
Van der Vlag J, Fakhouri F, Sethi S, Smith RJH, Lambris JD, Kavanagh D, Noris M, Blom AM, Fremeaux-Bacchi V, Remuzzi G, Appel GB, D'Agati VD, Nester CM, Zipfel PF, Pickering MC, Cook HT, Jozsi M, de Cordoba SR   +17 more
core   +4 more sources

Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice [PDF]

, 2018
Atypical hemolytic uremic syndrome (aHUS) is frequently associated in humans with loss-of-function mutations in complement-regulating proteins or gain-of-function mutations in complement-activating proteins.
Atkinson, John P, Marchbank, Kevin J, Cooke, Katie, Pappworth, Isabel Y, Liszewski, M Kathryn, Cook, H. T, Pickering, Matthew C, Kavanagh, David, Denton, Harriet, Barlow, Paul N, Liszewski, M. K, Cook, H Terence, Smith-Jackson, Kate, Yang, Yi   +13 more
core   +1 more source

Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin

, 2014
33 p.-4 fig.-2 fig. supl.Complement is an essential component of innate immunity. Its activation results in the assembly of unstable protease complexes, denominated C3/C5 convertases, leading to inflammation and lysis.
Llorca, Óscar, Rodríguez de Córdoba, Santiago, Tortajada, Agustín, Alcorlo, Martín   +3 more
core   +1 more source

Hyper-functional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice [PDF]

Atypical hemolytic uremic syndrome (aHUS) is frequently associated in humans with loss-of-function mutations in complement-regulating proteins or gain-of-function mutations in complement-activating proteins.
Cooke K, Liszewski MK, Yang Y, Pappworth IY, Marchbank KJ, Smith-Jackson K, Barlow PN, Atkinson JP, Cook T, Pickering MC, Kavanagh D, Denton H   +11 more
core   +4 more sources

Obesity and clustering of cardiovascular disease risk factors are associated with elevated plasma complement C3 in children and adolescents

, 2014
Objectives To investigate the relationship among obesity, cardiovascular disease risk factors (CVDRFs), and plasma complement C3 concentration in children and adolescents.
莊立民 ;李弘元, Wei, Jung-Nan;Li, Hung-Yuan;Sung, Fung-Chang;Lin, Chau-Ching;Chiang, Chuan-Chi;Carter, Angela M.;Chuang, Lee-Ming   +1 more
core  

Lessons from and for complement therapeutics: Novel mechanistic insights into terminal pathway activation and its linkage to thrombosis

In this cumulative dissertation, the precise mechanism of terminal pathway activation as well as the phenomenon of thromboembolic events in complement-related diseases have been elucidated.
Mannes, Marco
core   +1 more source

Characterizing Properdin-Inhibited C3 Nephritic Factors in Patients with Complement-Mediated Kidney Diseases. [PDF]

Int J Mol Sci
Stevens KH, Maas RJF, Volokhina EB, Toonen EJM, van de Kar NCAJ, van den Heuvel LPWJ, Michels MAHM.   +6 more
europepmc   +1 more source